Next Article in Journal
Neonatal Lupus Erythematosus as a Rare Cause of Fever in Young Infants
Previous Article in Journal
Concomitant Acute Ischemic Stroke and Upper Extremity Arterial Occlusion: Feasibility of Mechanical Thrombectomy of the Upper Limb Using Neurointerventional Devices and Techniques
Previous Article in Special Issue
In Patients with Early Peripheral Psoriatic Arthritis Baseline C-Reactive Protein, Pain and Ultrasound-Detected Synovitis Predict Subsequent Treatment with ts/bDMARDs. A Retrospective Analysis
Article

Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland

1
Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, CH-8093 Zurich, Switzerland
2
Rheumatology, Immunology and Allergy, Inselspital, University Hospital of Bern, CH-3010 Bern, Switzerland
3
Division of Rheumatology, University Hospitals of Geneva, CH-1206 Geneva, Switzerland
*
Author to whom correspondence should be addressed.
Academic Editors: Emmanuel Andres and Salvatore D’Angelo
J. Clin. Med. 2021, 10(14), 3194; https://doi.org/10.3390/jcm10143194
Received: 14 May 2021 / Revised: 18 June 2021 / Accepted: 15 July 2021 / Published: 20 July 2021
Abnormal body mass index (BMI) was associated with worse rheumatic markers in psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Aiming to describe PsA and RA patients stratified by BMI, we performed a descriptive study in PsA and RA patients (two distinct cohorts) in the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) registry. New users of biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) were stratified by BMI at the start of their treatment (underweight, normal weight, overweight, obese). The PsA underweight and normal weight categories were merged. Age at disease onset and further characteristics at the start of the first b/tsDMARD treatment were compared across BMI categories vs. the corresponding normal weight group. The study included 819 PsA (36.5% overweight, 23.8% obese) and 3217 RA patients (4.4% underweight, 31.8% overweight, 17.0% obese). Compared to the corresponding normal weight group, PsA and RA obese patients had significantly (p < 0.05) higher C-reactive protein, worse disease activity, and lower quality of life (QoL). Obese PsA patients had significantly worse skin manifestation and pain, while obese RA patients had significantly higher erythrocyte sedimentation rate and tender joint counts, as well as lower seropositive prevalence. To conclude, obese PsA and RA patients presented worse disease activity and poorer QoL than those with normal weight. View Full-Text
Keywords: psoriatic arthritis; rheumatoid arthritis; patient-reported outcomes; biologics psoriatic arthritis; rheumatoid arthritis; patient-reported outcomes; biologics
Show Figures

Figure 1

MDPI and ACS Style

Vallejo-Yagüe, E.; Burkard, T.; Möller, B.; Finckh, A.; Burden, A.M. Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland. J. Clin. Med. 2021, 10, 3194. https://doi.org/10.3390/jcm10143194

AMA Style

Vallejo-Yagüe E, Burkard T, Möller B, Finckh A, Burden AM. Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland. Journal of Clinical Medicine. 2021; 10(14):3194. https://doi.org/10.3390/jcm10143194

Chicago/Turabian Style

Vallejo-Yagüe, Enriqueta, Theresa Burkard, Burkhard Möller, Axel Finckh, and Andrea M. Burden 2021. "Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland" Journal of Clinical Medicine 10, no. 14: 3194. https://doi.org/10.3390/jcm10143194

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop